End-of-day quote
Shenzhen S.E.
03:30:00 22/05/2024 am IST
|
5-day change
|
1st Jan Change
|
12.45
CNY
|
-1.19%
|
|
+5.60%
|
-8.32%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
8,670
|
5,161
|
5,917
|
11,138
|
15,527
|
11,994
|
Enterprise Value (EV)
1 |
8,877
|
6,371
|
7,414
|
12,310
|
17,067
|
13,660
|
P/E ratio
|
-25.2
x
|
-6.04
x
|
-10.1
x
|
420
x
|
-41.9
x
|
-23.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.86
x
|
8.4
x
|
8.2
x
|
15.1
x
|
22
x
|
27.8
x
|
EV / Revenue
|
7.02
x
|
10.4
x
|
10.3
x
|
16.7
x
|
24.2
x
|
31.7
x
|
EV / EBITDA
|
32.5
x
|
-16.1
x
|
-16.8
x
|
-109
x
|
-292
x
|
-103
x
|
EV / FCF
|
-21
x
|
-14.3
x
|
-66.3
x
|
-72.7
x
|
-96.1
x
|
146
x
|
FCF Yield
|
-4.77%
|
-7.01%
|
-1.51%
|
-1.38%
|
-1.04%
|
0.68%
|
Price to Book
|
2.55
x
|
2.65
x
|
3.59
x
|
7.03
x
|
12.2
x
|
15
x
|
Nbr of stocks (in thousands)
|
9,28,267
|
8,89,843
|
8,89,843
|
8,83,241
|
8,83,241
|
8,83,241
|
Reference price
2 |
9.340
|
5.800
|
6.650
|
12.61
|
17.58
|
13.58
|
Announcement Date
|
24/04/19
|
28/04/20
|
29/04/21
|
27/04/22
|
26/04/23
|
26/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,264
|
614.2
|
721.7
|
736
|
704.3
|
431.4
|
EBITDA
1 |
273.4
|
-396.6
|
-441.7
|
-112.7
|
-58.4
|
-132.7
|
EBIT
1 |
177.7
|
-497
|
-545.3
|
-237
|
-182.1
|
-281.5
|
Operating Margin
|
14.05%
|
-80.92%
|
-75.55%
|
-32.2%
|
-25.86%
|
-65.25%
|
Earnings before Tax (EBT)
1 |
-333.7
|
-891.3
|
-588.2
|
33.68
|
-372.8
|
-511.1
|
Net income
1 |
-340.8
|
-884.8
|
-609.4
|
30.81
|
-370.6
|
-513.9
|
Net margin
|
-26.95%
|
-144.05%
|
-84.44%
|
4.19%
|
-52.61%
|
-119.12%
|
EPS
2 |
-0.3700
|
-0.9600
|
-0.6600
|
0.0300
|
-0.4200
|
-0.5800
|
Free Cash Flow
1 |
-423.4
|
-446.5
|
-111.9
|
-169.4
|
-177.6
|
93.41
|
FCF margin
|
-33.48%
|
-72.69%
|
-15.5%
|
-23.01%
|
-25.22%
|
21.65%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/04/19
|
28/04/20
|
29/04/21
|
27/04/22
|
26/04/23
|
26/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
207
|
1,210
|
1,496
|
1,173
|
1,540
|
1,665
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.7574
x
|
-3.05
x
|
-3.387
x
|
-10.4
x
|
-26.36
x
|
-12.55
x
|
Free Cash Flow
1 |
-423
|
-446
|
-112
|
-169
|
-178
|
93.4
|
ROE (net income / shareholders' equity)
|
-9.37%
|
-31.5%
|
-31.2%
|
1.71%
|
-25.3%
|
-49.6%
|
ROA (Net income/ Total Assets)
|
2.03%
|
-5.98%
|
-7.79%
|
-3.74%
|
-3.03%
|
-5.11%
|
Assets
1 |
-16,814
|
14,790
|
7,819
|
-824.5
|
12,236
|
10,060
|
Book Value Per Share
2 |
3.660
|
2.190
|
1.850
|
1.790
|
1.440
|
0.9100
|
Cash Flow per Share
2 |
1.690
|
0.8100
|
0.5100
|
0.1600
|
0.1200
|
0.4100
|
Capex
1 |
366
|
570
|
244
|
199
|
190
|
81.8
|
Capex / Sales
|
28.91%
|
92.83%
|
33.76%
|
27.04%
|
26.95%
|
18.95%
|
Announcement Date
|
24/04/19
|
28/04/20
|
29/04/21
|
27/04/22
|
26/04/23
|
26/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -8.32% | 1.52B | | +18.71% | 44.35B | | +20.29% | 15.08B | | +19.49% | 14.37B | | +57.58% | 13.06B | | -0.05% | 6.79B | | -9.70% | 6.75B | | -8.87% | 5.73B | | +13.66% | 5.64B | | +4.00% | 4.66B |
Generic Pharmaceuticals
|